Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet Lond Engl. 2017;389(10066):299–311. doi:10.1016/S0140-6736(16)30958-8
   PubMed Web of Science ®Google Scholar
• Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18(10):625–644. doi:10.1038/s41571-021-00520-1
   PubMed Web of Science ®Google Scholar
• Berger MJ, Ettinger DS, Aston J, et al. NCCN guidelines insights: antiemesis, version 2.2017. J Natl Compr Cancer Netw. 2017;15(7):883–893. doi:10.6004/jnccn.2017.0117
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(28):3240–3261. doi:10.1200/JCO.2017.74.4789
   PubMed Web of Science ®Google Scholar
• Roila F, Warr D, Hesketh PJ, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support Care Cancer. 2017;25(1):289–294. doi:10.1007/s00520-016-3365-1
   PubMed Web of Science ®Google Scholar
• Aogi K, Takeuchi H, Saeki T, et al. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol. 2021;26(1):1–17. doi:10.1007/s10147-020-01818-3
   PubMed Web of Science ®Google Scholar
• Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer Amst Neth. 2008;59(1):1–11. doi:10.1016/j.lungcan.2007.07.012
   PubMed Web of Science ®Google Scholar
• Rossi A, Chiodini P, Sun JM, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2014;15(11):1254–1262. doi:10.1016/S1470-2045(14)70402-4
   PubMed Web of Science ®Google Scholar
• DeRemer DL, Clemmons AB, Orr J, Clark SM, Gandhi AS. Emerging role of olanzapine for prevention and treatment of chemotherapy-induced nausea and vomiting. Pharmacotherapy. 2016;36(2):218–229. doi:10.1002/phar.1703
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Schnadig ID, Schwartzberg LS, et al. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer. 2016;122(15):2418–2425. doi:10.1002/cncr.30054
   PubMed Web of Science ®Google Scholar
• Weinstein C, Jordan K, Green SA, et al. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial. Support Care Cancer. 2018;26(11):3773–3780. doi:10.1007/s00520-018-4242-x
   PubMed Web of Science ®Google Scholar
• Ito Y, Karayama M, Inui N, et al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer Amst Neth. 2014;84(3):259–264. doi:10.1016/j.lungcan.2014.03.017
   PubMed Web of Science ®Google Scholar
• Kusagaya H, Inui N, Karayama M, et al. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer Amst Neth. 2015;90(3):410–416. doi:10.1016/j.lungcan.2015.11.009
   PubMed Web of Science ®Google Scholar
• Tanioka M, Kitao A, Matsumoto K, et al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer. 2013;109(4):859–865. doi:10.1038/bjc.2013.400
   PubMed Web of Science ®Google Scholar
• Yahata H, Kobayashi H, Sonoda K, et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol. 2016;21(3):491–497. doi:10.1007/s10147-015-0928-y
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Baba H, Takeda K, et al. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. Expert Opin Pharmacother. 2017;18(8):753–758. doi:10.1080/14656566.2017.1317746
   PubMed Web of Science ®Google Scholar
• Matsui R, Suzuki K, Takiguchi T, et al. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study. BMC Pharmacol Toxicol. 2020;21(1):72. doi:10.1186/s40360-020-00445-y
   PubMed Web of Science ®Google Scholar
• Shimokawa M, Hayashi T, Nishimura J, et al. Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk. BMC Cancer. 2021;21(1):1111. doi:10.1186/s12885-021-08860-y
   PubMed Web of Science ®Google Scholar
• Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med. 2005;24(20):3089–3110. doi:10.1002/sim.2174
   PubMed Web of Science ®Google Scholar
• Sugihara M. Survival analysis using inverse probability of treatment weighted methods based on the generalized propensity score. Pharm Stat. 2010;9(1):21–34. doi:10.1002/pst.365
   PubMed Web of Science ®Google Scholar
• Shimokawa M, Hayashi T, Kogawa T, et al. Evaluation of combination antiemetic therapy on CINV in patients with gynecologic cancer receiving TC chemotherapy. Anticancer Res. 2019;39(1):225–230. doi:10.21873/anticanres.13101
   PubMed Web of Science ®Google Scholar
• Hayashi T, Shimokawa M, Miyoshi T, et al. A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. Support Care Cancer. 2017;25(9):2707–2714. doi:10.1007/s00520-017-3679-7
   PubMed Web of Science ®Google Scholar
• Hayashi T, Shimokawa M, Matsuo K, et al. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis. BMC Cancer. 2021;21(1):74. doi:10.1186/s12885-021-07802-y
   PubMed Web of Science ®Google Scholar
• Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375(2):134–142. doi:10.1056/NEJMoa1515725
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Oncol. 2020;21(2):242–249. doi:10.1016/S1470-2045(19)30678-3
   PubMed Web of Science ®Google Scholar
• Tanaka K, Inui N, Karayama M, et al. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol. 2019;84(1):147–153. doi:10.1007/s00280-019-03868-5
   PubMed Web of Science ®Google Scholar
• Shimomura K, Minatogawa H, Mashiko T, et al. LBA63 Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial. Ann Oncol. 2021;32:S1339–S1340. doi:10.1016/j.annonc.2021.08.2144
   Web of Science ®Google Scholar
• Razvi Y, Chan S, McFarlane T, et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 2019;27(1):87–95. doi:10.1007/s00520-018-4464-y
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data. Curr Opin Oncol. 2020;32(4):269–273. doi:10.1097/CCO.0000000000000634
   PubMed Web of Science ®Google Scholar